Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peritoneal perfusion of drug-loaded vesicles after colorectal cancer surgery
ChiCTR2300078718Phase 4Not yet recruiting
- Sponsor
- Tianjin Third Central Hospital
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of AQ001S in colorectal cancer (CRC) (2 arms), sponsored by Tianjin Third Central Hospital. Primary endpoints: Immune cell subsets in peritoneal immune microenvironment and Postoperative complications. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
AQ001S
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2300078718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078718.